Chronic Obstructive Pulmonary Disease (COPD) Devices Market Size, Company Revenue Share, Key Drivers & Trend Analysis, 2023–2032

6 minutes, 56 seconds Read

The global Chronic Obstructive Pulmonary Disease (COPD) devices market size was USD 8.3 Billion in 2022 and is expected to register a revenue CAGR of 6% over the forecast period, according to the latest report by Reports and Data.

Emphysema, chronic bronchitis, and various respiratory ailments manifest as symptoms of COPD, which is a persistent respiratory affliction. Prolonged exposure to airborne pollutants, including smoking, dust, and other irritants, constitutes the primary etiology of this condition.

The market for COPD equipment, encompassing inhalers, nebulizers, oxygen concentrators, and other related devices, anticipates a surge in revenue growth due to the escalating prevalence of COPD on a global scale. The World Health Organization (WHO) has indicated that COPD presently stands as the third leading cause of mortality worldwide, with projections suggesting it will become the fifth most common cause of death by 2030. Furthermore, the heightened vulnerability of the elderly population to COPD underscores the indispensability of these medical apparatuses. According to the United Nations, the elderly demographic is projected to reach a staggering 1.5 billion by 2050, thereby fueling the expansion of market revenue.

Furthermore, there is a significant demand for non-invasive and portable COPD devices due to their ease of use and consistent diagnostic outcomes. This holds particularly true in the context of home care settings, where patients favor the convenience and user-friendly nature of mobile COPD devices. Moreover, advancements in technology have facilitated the creation of portable medical equipment, thereby spurring an anticipated increase in demand for such products throughout the projected timeframe.

Moreover, governmental initiatives aimed at mitigating the impact of COPD are bolstering market revenue. Governments worldwide are proactively addressing the need to enhance awareness regarding COPD, facilitate early detection, and promote effective treatment of the condition. As an illustration, the National Heart, Lung, and Blood Institute (NHLBI) in the United States has launched a program called ‘COPD Learn More Breathe Better.’ The primary objective of this endeavor is to augment public knowledge about COPD, encouraging individuals to undergo testing and seek appropriate treatment.

As per the World Health Organization, COPD ranks as the eighth most prevalent cause of mortality on a global scale, impacting approximately 384 million individuals worldwide.

In the United States alone, over 11 million individuals have received a diagnosis of COPD, with an additional 6 million projected to be affected by this ailment.

The U.S. Food and Drug Administration (FDA) assumes responsibility for overseeing the design and production of medical devices utilized in COPD treatment. Additionally, the FDA establishes criteria for conducting clinical trials, a prerequisite for obtaining approval for human usage of these devices.

The Centers for Medicare & Medicaid Services (CMS) establishes reimbursement standards for specific COPD treatment devices, including oxygen concentrators and nebulizers.

Get a sample of the report @

Some of the prominent players profiled in the global COPD devices market include GlaxoSmithKline plc, AstraZeneca plc, Philips Healthcare, Medtronic plc, Omron Healthcare Co., Ltd., ResMed Inc., Inogen Inc., Chart Industries, Inc., Koninklijke Philips N.V., Drägerwerk AG & Co. KGaA, and Teleflex Incorporated.

Some Key Highlights from the Report

  • In 2022, the inhalers segment captured the largest share of market revenue. Inhalers enjoy significant preference among individuals afflicted with COPD due to their portability and user-friendly nature. By delivering medication directly to the lungs, inhalers ensure improved treatment efficacy while minimizing the likelihood of adverse effects. Their straightforward usage necessitates minimal training. Moreover, inhalers contribute to reducing the necessity for hospitalizations and emergency room visits, resulting in substantial cost savings for both patients and healthcare providers.
  • In 2022, the hospital segment secured the largest portion of market revenue. Hospitals serve as the primary care setting for individuals with COPD, as the majority of hospitalizations and treatments for this condition are concentrated within their facilities. With their access to advanced diagnostic and therapeutic resources, hospitals are well-equipped to address the complex requirements of COPD patients. Moreover, their substantial patient volume allows for increased utilization of COPD devices, thereby driving sales within the market.
  • In 2022, the Asia Pacific region dominated the market with the largest share of revenue. The escalating prevalence of chronic obstructive pulmonary disease (COPD), notably in developing nations like China and India, serves as a catalyst for market growth within the region. Estimates indicate that these countries will experience the highest rates of COPD globally, attributed to factors such as smoking, air pollution, and an aging population.
  • The North American market is poised to exhibit the fastest revenue compound annual growth rate (CAGR) during the forecast period. This projection can be attributed to the high prevalence of chronic obstructive pulmonary disease (COPD) in the region, coupled with increasing public awareness regarding the condition and available treatment options. Notably, the prevalence of smoking in the region contributes significantly to the risk of developing COPD. The growth of market revenue in the region is further fueled by the rising elderly population.
  • On January 7, 2019, ResMed Inc. revealed its acquisition of Propeller Health, a cloud-based COPD monitoring company, for a sum of USD 225 million. This strategic acquisition aims to augment ResMed’s digital health portfolio and enhance patient outcomes.
  • On April 27, 2021, Medtronic plc obtained FDA approval for its Emprint Ablation System, designed for the treatment of lung cancer and other respiratory conditions, including COPD. The system employs a minimally invasive procedure to ablate lung tissue, resulting in improved lung function for patients.
  • GlaxoSmithKline plc: On April 26, 2022, GlaxoSmithKline introduced its Trelegy Ellipta inhaler, specifically designed for individuals suffering from COPD. This inhaler innovatively combines three active components within a single dose, enabling enhanced symptom management and facilitating ease of use for patients.

For the purpose of this report, Reports and Data has segmented the global COPD devices market on the basis of Product Type Outlook, End-use Outlook, and Regional Outlook:

Product Type Outlook (Revenue, USD Billion; 2022 – 2032)

  • Inhalers
  • Nebulizers
  • Oxygen Therapy Devices
  • Others

End-use Outlook (Revenue, USD Billion; 2022 – 2032)

  • Hospitals
  • Homecare Settings

Regional Outlook (Revenue, USD Billion; 2022-2032)

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Sweden
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • South Africa
    • Israel
    • Rest of MEA

Request a customization on the report @

Thank you for taking the time to read our article. The report can be tailored to the needs of the client. Please contact us for more details, and our team will tailor the report to your specific requirements.

Explore Trending Links:

Nanomedicine Market Size 2022-2030-Increasing Adoption Of Nanomedicine In Healthcare Sector –

Electronic Skin Market Insights, Future Trends, On-going Demand, Opportunities, Segmentation, and Forecast till 2027 –

Anesthesia Machine Market Size 2022-2028-  Increasing Number Of Surgical Procedures Is Major Factors Driving Growth Of Market –

DNA and Gene Chip Market Growth, Revenue Share Analysis, Company Profiles, and Forecast To 2028 –

Telehealth Market Size 2022-2028-  Increasing Need for Cost-effective Healthcare Assistance

Female Infertility Market Forecast –

Peripheral Nerve Injury Market Outlook –

Atrophic Vaginitis Treatment Market Companies –

About Us:

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyse consumer behaviour shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Power and Energy, and Chemicals. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web:

Direct Line: +1-212-710-1370

E-mail: [email protected]

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @

Browse More Latest Reports @

Browse Latest Blogs:

Browse Latest Press Release:

Browse Upcoming Reports:

Browse Press Release:

Similar Posts